EUVIMEDEUVIMED entdecken
Multizentrische Studie

Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier

Sara Ahmadi, Anupam Kotwal iD, Athanasios Bikas iD, Pingping Xiang, Whitney Goldner iD, Anery Patel iD, Elena G Hughes iD, Xochitl Longstaff iD, Michael W Yeh iD, Masha J Livhits iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae112 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Sara Ahmadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Thyroid Nodule. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Molecular testing can refine the risk of malignancy in thyroid nodules with indeterminate cytology to decrease unnecessary diagnostic surgery.

Objective

This study was performed to evaluate the outcomes of cytologically indeterminate thyroid nodules managed with Afirma genomic sequencing classifier (GSC) testing.

Methods

Adult patients who underwent a biopsy at 3 major academic centers between July 2017 and June 2021 with Bethesda III or IV cytology were included. All patients had surgery or minimum follow-up of 1 year ultrasound surveillance. The primary outcomes were the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of GSC in Bethesda III and IV nodules.

Results

The median nodule size of the 834 indeterminate nodules was 2.1 cm and the median follow-up was 23 months. GSC sensitivity, specificity, PPV, and NPV across all institutions were 95%, 81%, 50%, and 99% for Bethesda III nodules and 94%, 82%, 65%, and 98% for Bethesda IV nodules, respectively. The overall false-negative rate was 2%. The NPV of GSC in thyroid nodules with oncocytic predominance was 100% in Bethesda III nodules and 98% in Bethesda IV nodules. However, the PPV of oncocytic nodules was low (17% in Bethesda III nodules and 45% in Bethesda IV nodules). Only 22% of thyroid nodules with benign GSC results grew during surveillance.

Conclusion

GSC is a key tool for managing patients with indeterminate cytology, including the higher-risk Bethesda IV category. GSC-benign thyroid nodules can be observed similarly to thyroid nodules with benign cytology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleHumansMaleFemaleMiddle AgedAdultBiopsy, Fine-NeedleAgedRetrospective StudiesThyroid NeoplasmsPredictive Value of TestsSensitivity and SpecificityGenomicsFollow-Up Studies

Stichwörter der Autor:innen

Bethesda IVmolecular testthyroid nodule

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
  • Department of Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA 90095, USA.

ORCID-Profile: Anupam Kotwal, Athanasios Bikas, Whitney Goldner, Anery Patel, Elena G Hughes, Xochitl Longstaff, Michael W Yeh, Masha J Livhits

Zitieren

APA

Ahmadi, S., Kotwal, A., Bikas, A., Xiang, P., Goldner, W., Patel, A., Hughes, E. G., Longstaff, X., Yeh, M. W., & Livhits, M. J. (2024). Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae112

Vancouver

Ahmadi S, Kotwal A, Bikas A, Xiang P, Goldner W, Patel A, et al. Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae112

BibTeX
@article{Ahmadi2024,
  author = {Ahmadi, Sara and Kotwal, Anupam and Bikas, Athanasios and Xiang, Pingping and Goldner, Whitney and Patel, Anery and Hughes, Elena G and Longstaff, Xochitl and Yeh, Michael W and Livhits, Masha J},
  title = {Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae112}
}
Kostenlos starten →